Retail traders called Oscar Health undervalued, saying the digital insurer could benefit from Donald Trump plan to redirect Obamacare funds directly to citizens. The company reaffirmed its goal to reach profitability by 2026 after a narrower quarterly loss and strong FY25 outlook. UBS raised its price target to $12 from $11 but maintained a sell rating.